Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2023 | 81 | 4.770 |
Why?
|
| Renal Insufficiency, Chronic | 7 | 2025 | 174 | 3.600 |
Why?
|
| Huntington Disease | 8 | 2022 | 23 | 2.920 |
Why?
|
| Myotonic Dystrophy | 7 | 2023 | 13 | 2.800 |
Why?
|
| Brain | 16 | 2025 | 1319 | 2.360 |
Why?
|
| Survivors | 7 | 2023 | 128 | 1.790 |
Why?
|
| Child | 36 | 2025 | 6906 | 1.660 |
Why?
|
| Cleft Lip | 5 | 2021 | 41 | 1.480 |
Why?
|
| Cleft Palate | 5 | 2021 | 77 | 1.410 |
Why?
|
| Adolescent | 27 | 2025 | 6443 | 1.390 |
Why?
|
| Cognition | 4 | 2023 | 346 | 1.240 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2025 | 1548 | 1.200 |
Why?
|
| Neuropsychological Tests | 4 | 2021 | 355 | 1.180 |
Why?
|
| Quality of Life | 3 | 2024 | 851 | 1.170 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 189 | 1.090 |
Why?
|
| Memory, Short-Term | 5 | 2022 | 76 | 1.080 |
Why?
|
| Male | 37 | 2025 | 25907 | 1.000 |
Why?
|
| Leg | 3 | 2023 | 123 | 0.950 |
Why?
|
| Case-Control Studies | 8 | 2025 | 1156 | 0.940 |
Why?
|
| Rhabdomyosarcoma | 1 | 2024 | 10 | 0.900 |
Why?
|
| Humans | 50 | 2025 | 50503 | 0.900 |
Why?
|
| Adolescent Development | 2 | 2020 | 19 | 0.880 |
Why?
|
| Female | 33 | 2025 | 27081 | 0.860 |
Why?
|
| Intelligence | 2 | 2020 | 58 | 0.840 |
Why?
|
| Facial Expression | 2 | 2020 | 14 | 0.820 |
Why?
|
| Neuroimaging | 3 | 2021 | 87 | 0.820 |
Why?
|
| Neurofilament Proteins | 2 | 2022 | 3 | 0.810 |
Why?
|
| Child Development | 3 | 2020 | 192 | 0.780 |
Why?
|
| Glucocorticoids | 1 | 2023 | 230 | 0.740 |
Why?
|
| Adolescent Behavior | 2 | 2020 | 103 | 0.730 |
Why?
|
| Executive Function | 5 | 2023 | 76 | 0.700 |
Why?
|
| Young Adult | 13 | 2025 | 4102 | 0.700 |
Why?
|
| Child Behavior | 1 | 2020 | 106 | 0.670 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2019 | 4 | 0.640 |
Why?
|
| Psychomotor Performance | 2 | 2016 | 130 | 0.610 |
Why?
|
| Motor Activity | 1 | 2019 | 225 | 0.570 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1610 | 0.550 |
Why?
|
| Body Height | 2 | 2020 | 64 | 0.550 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 511 | 0.540 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2016 | 44 | 0.520 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1172 | 0.500 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 784 | 0.480 |
Why?
|
| Adult | 15 | 2024 | 13577 | 0.480 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 172 | 0.470 |
Why?
|
| Body Mass Index | 2 | 2020 | 677 | 0.440 |
Why?
|
| Cognition Disorders | 2 | 2020 | 213 | 0.430 |
Why?
|
| Amygdala | 2 | 2011 | 39 | 0.420 |
Why?
|
| Social Isolation | 1 | 2013 | 28 | 0.420 |
Why?
|
| Pituitary Gland | 1 | 2012 | 85 | 0.370 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2023 | 243 | 0.370 |
Why?
|
| Neoplasms | 1 | 2021 | 1251 | 0.360 |
Why?
|
| Motivation | 1 | 2013 | 275 | 0.360 |
Why?
|
| Sex Characteristics | 2 | 2010 | 198 | 0.350 |
Why?
|
| Risk Factors | 4 | 2024 | 3724 | 0.350 |
Why?
|
| Glomerular Filtration Rate | 3 | 2025 | 119 | 0.330 |
Why?
|
| Age Factors | 2 | 2025 | 1110 | 0.330 |
Why?
|
| Emotions | 2 | 2020 | 168 | 0.320 |
Why?
|
| Anxiety | 3 | 2024 | 285 | 0.320 |
Why?
|
| Fear | 1 | 2010 | 84 | 0.320 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 167 | 0.310 |
Why?
|
| Reaction Time | 3 | 2020 | 214 | 0.310 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2008 | 93 | 0.290 |
Why?
|
| Child, Preschool | 5 | 2024 | 3942 | 0.270 |
Why?
|
| Middle Aged | 6 | 2021 | 12611 | 0.270 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 209 | 0.260 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 735 | 0.260 |
Why?
|
| Corpus Striatum | 3 | 2022 | 51 | 0.260 |
Why?
|
| Alcoholism | 1 | 2008 | 235 | 0.250 |
Why?
|
| Anisotropy | 2 | 2023 | 64 | 0.240 |
Why?
|
| Intermediate Filaments | 2 | 2022 | 4 | 0.240 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2023 | 93 | 0.230 |
Why?
|
| Reading | 2 | 2021 | 85 | 0.220 |
Why?
|
| Waiting Lists | 1 | 2024 | 59 | 0.220 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2023 | 4 | 0.220 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2023 | 6 | 0.220 |
Why?
|
| Functional Neuroimaging | 1 | 2023 | 21 | 0.220 |
Why?
|
| Movement Disorders | 1 | 2022 | 14 | 0.210 |
Why?
|
| Folic Acid | 1 | 2023 | 139 | 0.200 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2022 | 7 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 201 | 0.190 |
Why?
|
| Trinucleotide Repeats | 1 | 2021 | 2 | 0.190 |
Why?
|
| Kidney | 2 | 2023 | 696 | 0.180 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 125 | 0.180 |
Why?
|
| Motor Skills | 1 | 2020 | 25 | 0.180 |
Why?
|
| Infant | 4 | 2024 | 3628 | 0.180 |
Why?
|
| Dyslexia | 1 | 2021 | 55 | 0.180 |
Why?
|
| Mutation | 3 | 2022 | 1280 | 0.170 |
Why?
|
| Sex Factors | 2 | 2020 | 712 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2024 | 363 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2019 | 120 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2021 | 573 | 0.150 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 17 | 0.150 |
Why?
|
| Heart Failure | 1 | 2024 | 528 | 0.150 |
Why?
|
| Saliva | 1 | 2018 | 55 | 0.150 |
Why?
|
| Leukemia | 1 | 2018 | 65 | 0.150 |
Why?
|
| Intelligence Tests | 1 | 2017 | 44 | 0.140 |
Why?
|
| Body Weight | 1 | 2020 | 517 | 0.140 |
Why?
|
| Problem Solving | 1 | 2017 | 43 | 0.140 |
Why?
|
| Educational Status | 2 | 2020 | 230 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2019 | 390 | 0.140 |
Why?
|
| Brain Injuries | 1 | 2018 | 159 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2024 | 6263 | 0.140 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 238 | 0.130 |
Why?
|
| Siblings | 1 | 2016 | 33 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2020 | 1270 | 0.130 |
Why?
|
| Aging | 1 | 2021 | 693 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 214 | 0.130 |
Why?
|
| Organ Size | 2 | 2020 | 223 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2021 | 2378 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2018 | 550 | 0.110 |
Why?
|
| Phenotype | 1 | 2016 | 739 | 0.110 |
Why?
|
| Galvanic Skin Response | 1 | 2013 | 23 | 0.110 |
Why?
|
| Feedback, Psychological | 1 | 2013 | 18 | 0.110 |
Why?
|
| Eye Movements | 1 | 2013 | 23 | 0.110 |
Why?
|
| Social Perception | 1 | 2013 | 27 | 0.110 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 3226 | 0.100 |
Why?
|
| Functional Laterality | 1 | 2013 | 89 | 0.100 |
Why?
|
| Brain Damage, Chronic | 1 | 2011 | 12 | 0.100 |
Why?
|
| Muscles | 2 | 2023 | 104 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 227 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 197 | 0.090 |
Why?
|
| Aged | 2 | 2021 | 9741 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2010 | 49 | 0.080 |
Why?
|
| Disease Progression | 2 | 2022 | 829 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2008 | 552 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2008 | 107 | 0.070 |
Why?
|
| Reward | 1 | 2008 | 115 | 0.070 |
Why?
|
| Choice Behavior | 1 | 2008 | 83 | 0.070 |
Why?
|
| Decision Making | 1 | 2008 | 272 | 0.070 |
Why?
|
| Prefrontal Cortex | 2 | 2022 | 86 | 0.060 |
Why?
|
| Tissue and Organ Procurement | 1 | 2024 | 50 | 0.050 |
Why?
|
| Graft Survival | 1 | 2024 | 159 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2024 | 172 | 0.050 |
Why?
|
| Neostriatum | 1 | 2022 | 10 | 0.050 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2022 | 2 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2023 | 171 | 0.050 |
Why?
|
| Methotrexate | 1 | 2022 | 72 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 127 | 0.050 |
Why?
|
| Visual Perception | 1 | 2021 | 35 | 0.050 |
Why?
|
| Verbal Behavior | 1 | 2021 | 35 | 0.050 |
Why?
|
| Language Development | 1 | 2021 | 28 | 0.050 |
Why?
|
| Heterozygote | 1 | 2021 | 83 | 0.050 |
Why?
|
| Urinary Tract | 1 | 2020 | 26 | 0.040 |
Why?
|
| Cerebrum | 1 | 2020 | 9 | 0.040 |
Why?
|
| Speech Disorders | 1 | 2020 | 16 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 971 | 0.040 |
Why?
|
| Mathematics | 1 | 2020 | 44 | 0.040 |
Why?
|
| Sleep | 1 | 2022 | 181 | 0.040 |
Why?
|
| Social Class | 1 | 2020 | 94 | 0.040 |
Why?
|
| Cerebellum | 1 | 2020 | 131 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 324 | 0.040 |
Why?
|
| Prognosis | 1 | 2024 | 1978 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2018 | 11 | 0.040 |
Why?
|
| Brain Mapping | 2 | 2011 | 225 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 2242 | 0.040 |
Why?
|
| Belgium | 1 | 2018 | 3 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 698 | 0.040 |
Why?
|
| Mothers | 1 | 2020 | 257 | 0.040 |
Why?
|
| CpG Islands | 1 | 2018 | 108 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 163 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2024 | 1033 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 465 | 0.030 |
Why?
|
| Echocardiography | 1 | 2018 | 400 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 372 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1436 | 0.030 |
Why?
|
| Games, Experimental | 1 | 2008 | 9 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 5687 | 0.020 |
Why?
|
| Punishment | 1 | 2008 | 22 | 0.020 |
Why?
|
| Cues | 1 | 2008 | 51 | 0.020 |
Why?
|
| Peer Group | 1 | 2008 | 56 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 13124 | 0.010 |
Why?
|